Waiting
Traitement de la connexion…

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Immunology and Infection / Lentiviral CRISPR/Cas9-Mediated Genome Editing…
JoVE Journal
Immunology and Infection

Un abonnement à JoVE est nécessaire pour afficher ce contenu. Connectez-vous ou commencez votre essai gratuit.

JoVE Journal Immunology and Infection
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
 

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Article DOI: 10.3791/59977-v • 08:14 min • October 3rd, 2019
October 3rd, 2019 •
1, 1, 1, 1, 1, 1, 1, 1, 1
1Hematovascular Biology Center, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine

Chapitres

résumé
Automatic Translation

Described are protocols for the highly efficient genome editing of murine hematopoietic stem and progenitor cells (HSPC) by the CRISPR/Cas9 system to rapidly develop mouse model systems with hematopoietic system-specific gene modifications.

Tags

Keywords: Lentiviral CRISPR/Cas9 Genome Editing Hematopoietic Cells Disease Models Transgene Delivery 293T Cells Viral Titer Bone Isolation Hematopoietic Stem Cells
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter